News
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE: PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly type of leukemia. The approval....
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now
Forty years is a long time. But it's not an unimaginably long time. For many Americans, 40 years is roughly the length of time they will spend or have spent in the workforce.Those years will end....
3 Top Biotech Stocks Under $5
The biotech field is littered with stocks under $5 that probably won't walk away from the crash landings that made them look so cheap. You'll be glad to know that sifting through the wreckage to....
These Stocks Have Tripled This Year
The stock market has made a lot of people rich since 2009, as several major benchmarks have tripled or even quadrupled during the past eight years. Yet for individual stocks, gains can come a lot....
3 Healthcare Stocks I'll Hold Forever
Fund managers who need to look busy might hate to admit it, but doing nothing is usually the best course of action for most investors. That doesn't mean it's a good idea to look the other way when....
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE: JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet Johnson & Johnson has
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts
Shares of Exelixis (NASDAQ: EXEL), a biotechnology company focused on the development of drugs to treat various types of cancer, moved steadily higher by a cool 10% in July, according to data from S&P
The 3 Best Buffett Stocks for Retirees
Quality and durability should be the two pillars of any retiree's stock portfolio. A company that has a long track record of success and a bright future thanks to durable competitive advantages is the
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a biotech company with a keen focus on developing therapies to treat ultra-rare diseases, moved steadily higher by 13% during the month of July
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company